The addition of tislelizumab to chemotherapy showed statistical and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone in patients with recurrent/metastatic nasopharyngeal cancer. These findings will be presented during the ASCO Plenary Series session taking place April 19, 2022, at 3:00 p.m. ET.
The American Society of Clinical Oncology (ASCO) today announced the establishment of the ASCO Center for Equity, Diversity, and Inclusion, which will advance the Society’s equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider oncology community. ASCO Chief Equity, Diversity and Inclusion Officer Sybil Green will serve as the Center’s inaugural vice president with lead responsibility for guiding and organizing the organization’s far-reaching external and internal EDI efforts.
The Association for Clinical Oncology (ASCO) today presented Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) with the annual Congressional Champion for Cancer Care Award in recognition of their commitment to legislation that focuses on medical innovation. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their care delivery teams.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Edward Balaban, DO, FACP, FASCO for his valuable contributions to ASCO’s advocacy efforts. The award recognizes volunteers who have gone above and beyond in the past year, advocating on behalf of patients and providers to improve cancer care and research.
Boston and Alexandria, VA – ASCO’s CancerLinQ® and Count Me In announced today a new collaboration that aims to allow cancer researchers to learn from every patient with cancer, by actively engaging patients as part of the clinical research enterprise. CancerLinQ – a real world oncology data technology platform developed by the American Society of Clinical Oncology (ASCO) – collects and aggregates de-identified EHR data from oncology practices across the United States to advance cancer care through quality improvement and research. Count Me In, a non-profit research initiative of the Broad Institute of MIT and Harvard, the Emerson Collective, and Dana-Farber Cancer Institute, provides patients with a mechanism to participate in cancer research by sharing their unique, de-identified medical information and history with cancer researchers and investigators.
The Association for Clinical Oncology (ASCO) congratulates Dr. Norman E. “Ned” Sharpless on his successful tenure as Director of the National Cancer Institute (NCI). During his five years at NCI, Dr. Sharpless guided the Institute to advance the goals of the Cancer Moonshot Initiative, including important work to modernize cancer clinical trials to reflect an improved understanding of biology and the new types of therapies available to treat cancer. We are hopeful that these efforts will endure even after Dr. Sharpless’ departure later this month.
While the Association for Clinical Oncology (ASCO) strongly believes in the stated mission of ARPA-H and its potential to innovate and expedite research, we are concerned that the Administration’s FY 2023 budget request invests in ARPA-H at the expense of the National Institutes of Health (NIH) and the National Cancer Institute (NCI)
Patients with advanced non-small cell lung cancer without EGFR/ALK mutations who were treated with toripalimab plus first-line chemotherapy had better progression-free survival and overall survival compared to patients who received chemotherapy alone, according to research from the CHOICE-01 trial.
In patients with previously untreated metastatic or unresectable melanoma, the combination of nivolumab and relatlimab continued to demonstrate a progression-free survival benefit compared to nivolumab alone. The combination also demonstrated for the first time a higher overall response rate according to follow-up data from the RELATIVITY-047 trial. These data will be presented during an ASCO Plenary Series session taking place March 15, 2022, at 5:00 p.m. ET.
ALEXANDRIA, Va. – Jeffrey Peppercorn, MD, MPH, has been appointed as the next Editor-in-Chief of JCO Oncology Practice (JCO OP), an American Society of Clinical Oncology (ASCO) journal. JCO OP publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality oncology care with an evolving value-based lens.
The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA).
Taking aspirin daily did not improve invasive disease-free survival (iDFS) in breast cancer patients, according to research being presented in the February 15, 2022 ASCO Plenary Series session.
Pancreatic cancer is a leading cause of cancer-related deaths; however, despite decades of research, limited progress has been made to improve survival. There are currently no FDA-approved treatment options for patients with pancreatic cancer that has progressed on first- and second-line chemotherapy. Sotorasib is active and well tolerated in patients with metastatic pancreatic cancer with a KRASG12C mutation, according to research being presented in the February 15, 2022, ASCO Plenary Series session.
A scoring algorithm that incorporated 290 genetic variants for prostate cancer (PHS290) accurately identified people with high or low lifetime risks of developing metastatic prostate cancer or dying from the disease. Based on the risk scores, people with an African ancestry had the highest risk of developing metastatic prostate cancer and dying of the disease. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 17-19, 2022, in San Francisco, California.